Cancer Research
Senolytics Fail to Protect Bone From Chemotherapy-Induced Loss
A mouse study finds that senolytic drugs cannot prevent chemotherapy-driven bone loss, challenging a leading hypothesis about its cause.
Research Paper
May 7, 2026 0
Results for "Dasatinib + Quercetin" in Cancer
20 articles
Cancer Research
HDAC Inhibitor Plus Checkpoint Blocker Tested in Advanced Lung Cancer Trial
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
Clinical Trial
May 7, 2026 0
Cancer Research
Common Sedative Dexmedetomidine Shows Unexpected Cancer-Fighting Properties
Widely-used anesthetic triggers immune system to attack tumors and enhances checkpoint inhibitor therapy effectiveness.
Research Paper
Mar 29, 2026 0
Cancer Research
Multi-Drug Cancer Strategy Blocks Key Growth Pathway Better Than Single Drugs
Combining two targeted drugs plus dietary changes shows superior cancer-fighting potential in lab studies of breast and endometrial cancers.
Research Paper
Apr 2, 2026 0
Cancer Research
New Cancer Drug Combo Boosts Immune System to Fight Aggressive Breast Cancer
Combining CSF1R inhibitor with chemotherapy enhanced immune response and improved outcomes in triple-negative breast cancer patients.
Research Paper
Mar 28, 2026 0
Cancer Research
Blocking Autophagy Supercharges Lung Cancer Immunotherapy Response
Adding an autophagy inhibitor to anlotinib plus PD-1 blockade dramatically reshapes the tumor microenvironment in NSCLC models.
Research Paper
May 22, 2026 0
Cancer Research
Post-Trastuzumab Deruxtecan Treatments Show Promise in HER2+ Breast Cancer
Real-world study of 664 patients reveals effective treatment options after T-DXd discontinuation, with low lung disease recurrence rates.
Research Paper
Apr 2, 2026 0
Cancer Research
Navitoclax Plus YM155 Combination Shows Promise Against Ovarian Cancer
Novel drug combination targets chemotherapy-resistant ovarian cancer cells and extends survival in preclinical models.
Research Paper
Mar 28, 2026 2
Cancer Research
Vitamin D Receptor Agonist Reshapes Pancreatic Cancer's Defensive Shield
A phase trial finds paricalcitol safely remodels the tumor microenvironment in metastatic pancreatic cancer, boosting immune cell infiltration.
Research Paper
May 26, 2026 0
Cancer Research
FGFR Inhibitor Achieves 42% Response Rate in Rare SDH-Deficient Stomach Tumors
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Research Paper
May 29, 2026 0
Cancer Research
New Drug Combo Shows 55% Response Rate Against Aggressive Lung Cancer Subtype
Tislelizumab plus anlotinib achieved promising results in treating advanced pulmonary sarcomatoid carcinoma with manageable side effects.
Research Paper
Mar 28, 2026 0
Cancer Research
Immunotherapy Plus T-DXd Shows Strong Results in HER2-Low Breast Cancer
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
Research Paper
Jun 9, 2026 0
Cancer Research
Novel Dimeric Radiotracer Plus mTOR Inhibitor Shows Promise Against Cancer
Researchers developed a new radiotracer that targets cancer cells more effectively when combined with mTOR inhibition therapy.
Research Paper
Apr 3, 2026 0
Cancer Research
FDA Approves Oral AML Therapy for Elderly Patients Unfit for Intensive Chemo
Inqovi gains approval for newly diagnosed AML in patients 75+ or with comorbidities, offering a gentler oral treatment route.
Drug Approval
May 22, 2026 0
Cancer Research
New RAS Inhibitor Shows Promise Against Hard-to-Treat Bile Duct Cancer
A next-gen RAS inhibitor called daraxonrasib targets KRAS-mutant cholangiocarcinoma, showing strong preclinical results and early clinical activity.
Research Paper
Apr 27, 2026 0
Cancer Research
Chemotherapy Awakens Dormant Cancer Cells Through Neutrophil Traps
Study reveals how common cancer drugs trigger dormant tumor cells to reactivate and spread, offering new prevention strategies.
Research Paper
Mar 29, 2026 1
Cancer Research
New Drug Combination Shows Promise Against Treatment-Resistant Breast Cancer
Scientists discover how to make aggressive triple-negative breast cancer vulnerable to existing targeted therapy.
Research Paper
Mar 29, 2026 3
Cancer Research
FDA Grants Expanded Approval to Zongertinib for HER2-Mutant Lung Cancer
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Drug Approval
May 6, 2026 0
Cancer Research
Common Supplement PQQ Found to Block Cancer-Driving Enzyme in Lymphoma Cells
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
Research Paper
Apr 23, 2026 0
Cancer Research
New ADC Drug Shows Promise in Lung Cancer With Key Biomarker Clues
A phase 2 trial of datopotamab deruxtecan in 100 NSCLC patients reveals a 26% response rate and critical resistance biomarkers.
Research Paper
Apr 20, 2026 0
Page 1 of 2Next